Physician profile
Arvin L Aranda
NPI 1609864792
$4,203.79
in general payments reported to CMS, 2019-2025
14 companies · $481 in 2025
The $481 reported for 2025 was more than what a typical Family Medicine provider received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $27.52 · 2020: $175 · 2021: $683 · 2022: $1,023 · 2023: $646 · 2024: $1,169 · 2025: $481.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,296.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,295.51 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals Lp | $1,397.60 | 2020-2025 | Airsupra, Farxiga |
| Abbvie INC. | $895.81 | 2021-2024 | Ubrelvy, Qulipta, Vraylar |
| Novo Nordisk INC | $775.25 | 2019-2025 | Rybelsus, Ozempic, Wegovy |
| Pfizer INC. | $280.91 | 2020-2025 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $152.32 | 2022-2023 | Spiriva Respimat |
| Lilly USA, LLC | $143.56 | 2020-2022 | |
| Exact Sciences Corporation | $113.74 | 2023-2024 | Cologuard Collection Kit |
| Janssen Pharmaceuticals, INC | $112.47 | 2021-2022 | |
| Phathom Pharmaceuticals, INC. | $97.19 | 2024-2025 | Voquezna |
| E.R. Squibb & Sons, L.L.C. | $95.10 | 2021-2024 | Eliquis, Camzyos |
| Amgen INC. | $63.06 | 2022-2024 | Repatha, Otezla |
| Merck Sharp & Dohme LLC | $39.13 | 2019-2025 | Gardasil 9, Vaxelis, Capvaxive |
| Glaxosmithkline, LLC. | $25.56 | 2020-2022 | |
| Allergan, INC. | $12.09 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Arvin Aranda listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.